Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 52291-52300 Newer>

The Motley Fool September 30, 2011 John Rosevear	This Common Move Will Kill Your Retirement Sometimes, the "right thing to do" is actually the wrong thing to do. You can buy stocks that will let you sleep at night -- while still giving you returns that should handily outpace those of the CD or bond fund you were going to buy instead.
The Motley Fool September 30, 2011 Matt Koppenheffer	Bridgepoint Education Shares Dropped: What You Need to Know Shares of for-profit education company Bridgepoint Education were getting schooled by the bears today as they fell as much as 10% in intraday trading on more dour regulatory news.
The Motley Fool September 30, 2011 Alyce Lomax	Highway Robbery at Public Companies When companies say "stand and deliver," shareholders need to take a stand.
The Motley Fool September 30, 2011 Robert Eberhard	Sprint Nextel Pins Its Hope on iPhone The third-largest mobile phone provider adds an industry leader to its phone offerings.
The Motley Fool September 30, 2011 Alex Dumortier	Raytheon: Compounding or Destroying Value? With shares trading at 7.6 times its earnings-per-share estimate for the next 12 months, the share buyback program looks like a good use of shareholder capital at these prices.
The Motley Fool September 30, 2011 Alex Dumortier	Accenture: Creating or Destroying Value? With shares trading at 14.3 times its earnings-per-share estimate for the next 12 months, the share buyback program looks like a decent use of shareholder capital at these prices.
The Motley Fool September 30, 2011 Brian Orelli	When You Need More Than Just a Low-Margin Business Teva Pharmaceuticals, arguably the largest generic-drug maker, can use economies of scale more easily than smaller companies like Watson Pharmaceuticals or Par Pharmaceutical, but it's still pushing further into branded drugs.
The Motley Fool September 30, 2011 Brian Orelli	We Don't Care if It's the First Lupus Drug in 50 Years The U.K.'s National Institute for Health and Clinical Excellence declines Glaxo and HGS' Benlysta.
The Motley Fool September 30, 2011 Matt Koppenheffer	5 Stocks That Could Be Quick Doubles You want a 100% gain? Check out these five stocks that could be in line for a double.
The Motley Fool September 30, 2011 Travis Hoium	Gaming Stocks Are Starting to Look Cheap After a recent fall in stock prices gaming stocks are looking pretty attractive.
<Older 52291-52300 Newer> Return to current articles.